Skip To Main Content
Le contenu de ce site web est exclusivement réservé aux professionnels de santé en Belgique et au Luxembourg.
Campus
  • Aires thérapeutiques
  • Ressources
  • Éducation
  • Divers
Campus
  • Aires thérapeutiques
  • Ressources
  • Éducation
  • Divers

Articles

Sort by

Filtres

Réinitialiser
  • Aires thérapeutiques

Le pouvoir de réduire le chaos lié au VRS

Explorer

When to Initiate Basal Insulin?

Practical Guidance based on the 2022 ADA/EASD Guidelines.

Explorer

Approach for patients with peripheral artery disease (PAD) + T2DM: focus on LDL-C control

Explorer

Cardiovascular diseases (CVDs) are the leading cause of death globally

Explorer

Is Glycemic Control the Key to Preventing Long-term Complications in Type 2 Diabetes?

(Based on the study: Stratton IM, et al. BMJ. 2000;321(7258):405-12).

Explorer

How Does Glycaemic Control Impact Complications in Type 2 Diabetes?

Summary of The UK Prospective Diabetes Study (UKPDS).

Explorer

Why is Glycaemic Control in Type 2 Diabetes Still a Challenge?

Summary of Aschner P, et al. Diabetologia. 2020;63(4):711-721.

Explorer

What is TTP? A rare, life-threatening medical emergency

Early diagnosis and treatment of Thrombotic thrombocytopenic purpura (TTP) can help prevent the high risk of early deaths.

Explorer

When to suspect TTP?

TTP is rare and presents similarly to other thrombotic microangiopathies (TMAs), making it difficult to diagnose.

Explorer

Signs and symptoms of aTTP

Know the signs and symptoms of acquired TTP (aTTP).

Explorer

The Complex Burden of Autoimmune Type 1 Diabetes

Explorer

Why choose PRALUENT®?

The usual starting dose for PRALUENT is 75 mg administered subcutaneously once every 2 weeks. Patients requiring larger LDL-C reduction (>60%) may be started on 150 mg once every 2 weeks, or 300 mg once every 4 weeks (monthly), administered subcutaneously.2

Explorer